Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tobramycin-neomycin cross-sensitivity

W F Schorr, H B Ridgway

    Contact Dermatitis
    |June 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Neomycin-allergic patients may react to ophthalmic tobramycin. Patch testing with 20% tobramycin is recommended before prescribing to avoid allergic contact dermatitis.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Erythema multiforme (Stevens-Johnson syndrome) following deep radiation therapy.

    Cutis·1993
    Same author

    Iatrogenic Cushing's syndrome in a dog from owner's topical corticosteroid.

    Archives of dermatology·1993
    Same author

    Acquired pseudo-mongolian spot associated with minocycline therapy.

    Archives of dermatology·1992
    Same author

    Prevalence and relevance of allergic reactions in patients patch tested in North America--1984 to 1985.

    Journal of the American Academy of Dermatology·1989
    Same author

    Eosinophilic cellulitis (Wells' syndrome): histologic and clinical features in arthropod bite reactions.

    Journal of the American Academy of Dermatology·1984
    Same author

    Serious systemic disease: what are the skin signs?

    Geriatrics·1982
    Same journal

    Reply to: Acrylate Copolymers/Crosspolymers in Sunscreens: Minimally Allergenic, Without Evidence of Need for Avoidance by (Meth)acrylate-Sensitized Individuals.

    Contact dermatitis·2026
    Same journal

    Contact Allergy and Allergic Contact Dermatitis From Propylene Glycol and Related Glycols: Cosmetic Skin Sensitisers After All?

    Contact dermatitis·2026
    Same journal

    Acrylate Copolymers/Crosspolymers in Sunscreens: Minimally Allergenic, Without Evidence of Need for Avoidance by (Meth)Acrylate-Sensitized Individuals.

    Contact dermatitis·2026
    Same journal

    AI-Assisted Automated Two-Stage Patch Test Interpretation System Using Vision Transformer.

    Contact dermatitis·2026
    Same journal

    Use of Tralokinumab in a Hairdresser With Severe Chronic Hand Eczema and Occupational Allergic Contact Dermatitis.

    Contact dermatitis·2026
    Same journal

    Occupational Allergic Contact Dermatitis Caused by Cyclohexyl Diethanolamine in a Metalworking Fluid.

    Contact dermatitis·2026
    See all related articles

    Area of Science:

    • Dermatology
    • Ophthalmology
    • Allergology

    Background:

    • Neomycin is a common cause of allergic contact dermatitis.
    • Tobramycin is a new ophthalmic aminoglycoside antibiotic.
    • Cross-reactivity between neomycin and tobramycin is a clinical concern.

    Purpose of the Study:

    • To evaluate the potential for cross-reactivity between neomycin and tobramycin.
    • To determine the safety of ophthalmic tobramycin in neomycin-allergic patients.

    Main Methods:

    • Patch testing of normal volunteers with neomycin and varying concentrations of tobramycin.
    • Patch testing of neomycin-allergic patients with neomycin and tobramycin (10% and 20%).

    Main Results:

    Related Experiment Videos

  • No reactions were observed in normal volunteers.
  • All neomycin-allergic patients reacted to neomycin.
  • 60% and 65% of neomycin-allergic patients reacted to 10% and 20% tobramycin, respectively.
  • A significant percentage of neomycin-allergic patients showed positive reactions to tobramycin.

    • Conclusions:

    • Ophthalmic tobramycin should not be used in known neomycin-allergic patients without prior patch testing.
    • Patch testing with 20% tobramycin in white petrolatum is recommended.
    • Approximately 65% of neomycin-allergic patients may experience dermatitis with tobramycin therapy.